The estimated Net Worth of Robert L Jr Parkinson is at least $19.3 Million dollars as of 5 August 2013. Robert Parkinson owns over 25,000 units of Baxter International stock worth over $19,261,346 and over the last 21 years Robert sold BAX stock worth over $0.
Robert has made over 6 trades of the Baxter International stock since 2004, according to the Form 4 filled with the SEC. Most recently Robert exercised 25,000 units of BAX stock worth $871,250 on 5 August 2013.
The largest trade Robert's ever made was exercising 725,750 units of Baxter International stock on 31 July 2013 worth over $25,292,388. On average, Robert trades about 54,843 units every 125 days since 2004. As of 5 August 2013 Robert still owns at least 490,485 units of Baxter International stock.
You can see the complete history of Robert Parkinson stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is ONE BAXTER PARKWAY, , DEERFIELD,, IL, 60015.
Over the last 22 years, insiders at Baxter International have traded over $966,809,165 worth of Baxter International stock and bought 178,227 units worth $6,261,495 . The most active insiders traders include Point Llc Loeb Daniel S Third, Michael F Mahoney, and Jeffrey A Craig. On average, Baxter International executives and independent directors trade stock every 37 days with the average trade being worth of $3,609,738. The most recent stock trade was executed by Jeanne K Mason on 1 March 2024, trading 64,488 units of BAX stock currently worth $2,397,019.
baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.
Baxter International executives and other stock owners filed with the SEC include: